NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/24/2023
Back to search
Official data from USPTO
CERETYPE NEUROMEDICINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CERETYPE NEUROMEDICINE
ST13
US500000088740575Class
42, 44
Filing
88740575
Registration
7202269
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
10/24/2023
Trademark type
Word
Nice classes
42, 44
Filing date
12/27/2019
Registration date
10/24/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/24/2023
Last transaction
10/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/31/2023
First use in commerce
07/31/2023
Drawing code
4
Owner type
03
Owner location
CAMBRIDGE, MA, US
Examiner
CASTRO, GIANCARLO
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CERETYPE NEUROMEDICINE, INC.
Compass Neurosciences, Inc.
Representatives
Miguel Danielson Danielson Legal LLC
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Software as a service (SAAS) services featuring functional Magnetic Resonance Imaging (fMRI) for use in mental health disorder diagnosistreatment and prevention as well as for use in scientific collaborationsharing and analysis of data and for the presentation and dissemination of results; providing online non-downloadable software for interpreting neuro and brain scans; providing an online non-downloadable integrated suite of fMRIdiagnosticprevention and treatment software for use in mental health disorder diagnosistreatment and prevention as well as for use in scientific collaborationsharing and analysis of data and for the presentation and dissemination of results; analytic and consulting services for the use of neuroimaging technology to improve the utility of non-pharmacological therapeutic interventions for neuropsychiatric disorders; technological consulting and analytical services provided to MRI scanner manufacturersimage analysis companiesfunctional MRI device companies and academic institutions; pharmaceutical drug development services
Class 44
Medical consulting in the field of mental health disorders
Publications
History of USPTO decisions and trademark events.
43 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/24/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/22/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/21/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/29/2023
IUAF
USE AMENDMENT FILED
08/26/2023
EISU
TEAS STATEMENT OF USE RECEIVED
08/26/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/07/2023
EX5G
SOU EXTENSION 5 GRANTED
03/06/2023
EXT5
SOU EXTENSION 5 FILED
02/27/2023
EEXT
SOU TEAS EXTENSION RECEIVED
02/27/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/03/2022
EX4G
SOU EXTENSION 4 GRANTED
08/01/2022
EXT4
SOU EXTENSION 4 FILED
08/01/2022
EEXT
SOU TEAS EXTENSION RECEIVED
08/01/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/17/2022
EX3G
SOU EXTENSION 3 GRANTED
02/15/2022
EXT3
SOU EXTENSION 3 FILED
02/15/2022
EEXT
SOU TEAS EXTENSION RECEIVED
02/15/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/09/2021
EX2G
SOU EXTENSION 2 GRANTED
09/08/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
09/01/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/24/2021
EXT2
SOU EXTENSION 2 FILED
08/20/2021
EEXT
SOU TEAS EXTENSION RECEIVED
08/20/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/19/2021
EX1G
SOU EXTENSION 1 GRANTED
02/17/2021
EXT1
SOU EXTENSION 1 FILED
02/17/2021
EEXT
SOU TEAS EXTENSION RECEIVED
02/17/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/07/2020
PUBO
PUBLISHED FOR OPPOSITION
07/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/17/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/28/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/16/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/15/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/15/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/25/2020
GNRT
NON-FINAL ACTION E-MAILED
03/25/2020
CNRT
NON-FINAL ACTION WRITTEN
03/25/2020
DOCK
ASSIGNED TO EXAMINER
03/21/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2020
NWAP
NEW APPLICATION ENTERED
12/31/2019
Continuous trademark protection
Get notified about every new filing that threatens CERETYPE NEUROMEDICINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.